BCDA - BioCardia, Inc.
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.1400 |
| Open | 4.0500 |
| Bid | 2.9500 x 2200 |
| Ask | 4.1400 x 1000 |
| Day's Range | 4.1400 - 4.1400 |
| 52 Week Range | 2.1000 - 17.5000 |
| Volume | 676 |
| Avg. Volume | 10,763 |
| Market Cap | 28.352M |
| Beta (5Y Monthly) | 2.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4860 |
| Earnings Date | May 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 |
Fair Value
Related Research
- GlobeNewswire
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., May 15, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
SAN CARLOS, Calif., May 05, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
Biocardia Announces FDA-Recommended Modifications to Primary Endpoint for Cardiamp Cell Therapy Heart Failure Trial to Support Marketing Approval
BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP® Cell Therapy Heart Failure Trial and associated statistical analysis plan. The primary endpoint going forward will be an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that first compares each subject to each other subject for occurrence of first-tier events (time to death, in this case) and then compares patient outcomes for subsequent tiers.
- GlobeNewswire
BioCardia Awarded New U.S. Patent Covering Helix System for Local Biotherapeutic Delivery of Autologous and Allogenic Cells to the Heart
SAN CARLOS, Calif., April 28, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
BioCardia Announces Litigation Financing in the Case Captioned Boston Scientific Corp., et al., v. BioCardia Inc.
BioCardia®, Inc. (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported it has entered into an agreement for litigation financing which has been filed today with the Securities and Exchange Commission on Form 8-K. BioCardia, Inc. entered into a Litigation Funding Agreement with BSLF, L.L.C., an entity owned and controlled by Andrew Blank, a member of BioCardia’s board of directors, for the purpose of funding the Company’s currently pending legal proceedings and any and all claims, actions and/or proceedings relating to, or arising from, the case captioned Boston Scientific Corp., et al., v. BioCardia Inc., Case No. 3:19-05645-VC, U.S.D.C., N. D. Cal (the “Litigation”).
- GlobeNewswire
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
SAN CARLOS, Calif., April 09, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
Seasoned Biotech Financial Executive, Jay M. Moyes, Joins Sera Prognostics
Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical stage company into a rapidly growing commercial organization. For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies.
- GlobeNewswire
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ Heart Failure Trial, based on a review of all available safety data for all patients randomized in the trial. The DSMB indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide.
- Simply Wall St.
Should You Take Comfort From Insider Transactions At BioCardia, Inc. (NASDAQ:BCDA)?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- GlobeNewswire
BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL
BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) is expected to report on a prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which will be available for release on Tuesday, March 31, 2020. BioCardia will host a conference call/webcast to provide updates on the CardiAMP Heart Failure Trial featuring national co-principal investigators, Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville, on Tuesday, March 31 at 4:15 p.m. ET. A replay of the webcast will be available for a limited time on the BioCardia website following the presentation.
- Simply Wall St.
Does BioCardia, Inc.'s (NASDAQ:BCDA) CEO Pay Compare Well With Peers?
In 2002 Peter Altman was appointed CEO of BioCardia, Inc. (NASDAQ:BCDA). First, this article will compare CEO...
- GlobeNewswire
Biocardia Announces FDA Clearance for Morph DNA Deflectable Guide Catheter
SAN CARLOS, Calif., Jan. 14, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
BioCardia Announces New U.S. Patent Covering CardiAMP Cell Therapy and Issuance of Two Asian Patents Covering Radial Artery Approach for Cardiac Cell and Gene Therapy Delivery
BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of three new patents for the company’s technologies in the U.S., China and Japan. The new U.S. patent relates to the cell potency assay used in its CardiAMP™ Cell Therapy System, issued as U.S. Patent No: 10,520,505. The patent is for “Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies.” The Company also has European patent coverage for this technology.
- Simply Wall St.
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights
SAN CARLOS, Calif., Nov. 19, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- Simply Wall St.
Investors Who Bought BioCardia (NASDAQ:BCDA) Shares A Year Ago Are Now Down 80%
BioCardia, Inc. (NASDAQ:BCDA) shareholders should be happy to see the share price up 21% in the last month. But that...
- GlobeNewswire
BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference
SAN CARLOS, Calif., Oct. 28, 2019 -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024
SAN CARLOS, Calif., Oct. 08, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.
- GlobeNewswire
BioCardia Announces the Appointment of Two New Board Members
BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of experienced CEOs Jim Allen and Andrew Blank to its Board of Directors, effective October 1, 2019. Mr. Allen is Chief Executive Officer and President of Sea Star, Inc., a real estate development company, and has served in that capacity since he founded the company in February 1989. Six of his ventures have resulted in sales to publicly-traded companies.
- GlobeNewswire
BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
SAN CARLOS, Calif., Oct. 01, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.
- GlobeNewswire
BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned
The ongoing multi-center, double-blinded, randomized (3:2), sham-controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. Secondary efficacy endpoints include quality of life as measured by the Minnesota Heart Failure Quality of Life self-assessment, and superiority relative to MACE and survival.
- GlobeNewswire
BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 21, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
- GlobeNewswire
BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery
Today, autologous cardiac cell therapy – where a patient’s own cells are used – is challenged by patient variation, which makes outcomes unpredictable, and by the high costs associated with manufacturing single-batch therapy remotely for each patient. BioCardia’s new patent addresses a potential solution to these problems – a diagnostic approach for patient selection that identifies a specific biomarker signature in a patient’s bone marrow. This test enables a physician to determine if a patient is a good candidate for either of the Company’s two lead clinical indications of heart failure or chronic myocardial ischemia prior to treatment, allowing for point-of-care processing of the therapy and eliminating the significant expense of selecting and processing cells remotely.
- GlobeNewswire
BioCardia Announces Closing of $10.0 Million Public Offering
BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the closing of its previously announced public offering of 1,666,667 units at a price to the public of $6.00 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.30 per share. The common stock and warrants were immediately separable from the units and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 2, 2019, under the symbols “BCDA” and “BCDAW,” respectively.
- GlobeNewswire
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 1,666,667 units at a price to the public of $6.00 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.30 per share. The common stock and warrants will be immediately separable from the units and will be issued separately.
